IVVD logo

IVVD Invivyd, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$0.72
+0.04 (+5.13%)

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management an…

Market Cap: $212.38Mwww.invivyd.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

90
90
Aug 13Aug 13

Quote

Day Range
$0.66 – $0.73
52-Week Range
$0.48 – $3.07
Volume
$2.02M
Market Cap
$212.38M
50-Day Avg
$0.78
200-Day Avg
$1.56
Prev Close
$0.69
Open
$0.69

Valuation & Ratios

P/E Ratio
-8.23
EPS
$-0.30
P/B Ratio
1.76
P/S Ratio
7.96
Debt/Equity
0.01
Current Ratio
7.24
Dividend Yield
+0.0%
Gross Margin
+93.0%

Returns & Efficiency

Return on Equity
-21.7%
Return on Assets
-19.0%
FCF Yield
-13.7%
EV/EBITDA
-3.99

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$53.43M$-52.49M$-0.30
2024$25.38M$-169.93M$-1.43
2023$0.00$-198.64M$-1.81
2022$0.00$-241.32M$-2.17
2021$0.00$-226.79M$-2.11

Social Signal Score

41
5d
41
2 mentions
30d
41
2 mentions
60d
41
2 mentions
90d
41
2 mentions
news: 2

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.11 per share

2of 7 quarters beat consensus

Typical surprise -31.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.14 vs $-0.11miss
  • Thu, May 14$-0.13 vs $-0.08miss
  • Thu, Mar 5$0.02 vs $-0.06beat
  • Thu, Nov 6$-0.06 vs $-0.05miss
  • Thu, Aug 14$-0.12 vs $-0.04miss
  • Thu, May 15$-0.14 vs $-0.04miss

Estimates and results for IVVD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

IVVDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newszacks.com·1d ago·Negative

    Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.

    View source ↗
  • Newsglobenewswire.com·1d ago·Neutral

    Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.

    View source ↗